Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model

Influence of acquired  -lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli

(2012) M. Adler et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility ofKlebsiella pneumoniaeIsolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

(2011) Stephen P. Hawser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009)

(2011) S.P. Hawser et al.   CLINICAL MICROBIOLOGY AND INFECTION

Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children

(2011) Nazan Dalgic et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum- -lactamase-producing Gram-negative organisms

(2010) R. Bazaz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phenotypic and Genotypic Characterization of Enterobacteriaceae with Decreased Susceptibility to Carbapenems: Results from Large Hospital-Based Surveillance Studies in China

(2009) Q. Yang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli

(2007) J. Rodríguez-Baño et al.   CLINICAL MICROBIOLOGY AND INFECTION